Non alcoholic fatty liver disease: a clinical approach and review.

Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World J Gastroenterol (2006) 1.03

The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis (2010) 1.03

Etiopathogenesis of nonalcoholic steatohepatitis: role of obesity, insulin resistance and mechanisms of hepatotoxicity. Int J Hepatol (2012) 0.95

New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetol Metab Syndr (2011) 0.94

Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci (2007) 0.93

Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci (2008) 0.87

Congenital and environmental factors associated with adipocyte dysregulation as defects of insulin resistance. Rev Diabet Stud (2007) 0.84

Impact of Roux-en-Y gastric bypass on regulation of diabetes type 2 in morbidly obese patients. Surg Endosc (2012) 0.79

Predictors of non-alcoholic fatty liver disease in obese and overweight Egyptian children: single center study. Saudi J Gastroenterol (2011) 0.78

Hepatitis virus C infection, adipokines and hepatic steato-fibrosis. J Med Life (2010) 0.75

The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67

Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA (2005) 9.61

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09

The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med (2005) 5.38

Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 5.22

Meta-analysis: surgical treatment of obesity. Ann Intern Med (2005) 5.17

Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med (2000) 4.92

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2003) 4.05

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology (1999) 3.99

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA (1999) 3.56

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol (2001) 3.16

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98

Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis (2001) 2.63

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol (2001) 2.11

Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol (2004) 1.98

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol (2005) 1.93

Dietary fat and alcoholic liver disease. Hepatology (1998) 1.75

Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg (2005) 1.70

Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2004) 1.70

Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2004) 1.68

Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev (2004) 1.62

Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2004) 1.60

Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol (2002) 1.31

The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res (2005) 1.23

Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. Am J Clin Nutr (2004) 1.11

Obesity and liver disease. Best Pract Res Clin Endocrinol Metab (2002) 1.00

The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol (2003) 0.98

Role of hyperinsulinemia and glucose intolerance in the pathogenesis of nonalcoholic fatty liver in patients with normal body weight. Korean J Intern Med (1998) 0.90

Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother (2003) 0.86

Orlistat in the treatment of NASH: a case series. Am J Gastroenterol (2003) 0.84

Is adiponectin level a predictor of nonalcoholic fatty liver disease in nondiabetic male patients? World J Gastroenterol (2005) 0.77